SuperworthProtalix BioTherapeutics EPS PLX
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.23
- Latest quarter, Q2 FY26
- $0.05
- Fiscal year 2025
- −$0.09
- −550% on the year before
Protalix BioTherapeutics' earnings per share was $0.23 over the twelve months to Jun 30, 2026, up 283% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.05.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.09 | −550% |
| FY2024 | $0.02 | −50% |
| FY2023 | $0.04 | n/a |
| FY2022 | −$0.30 | n/a |
| FY2021 | −$0.63 | n/a |
| FY2020 | −$0.16 | n/a |
| FY2019 | −$1.24 | n/a |
| FY2018 | −$1.90 | n/a |
| FY2017 | −$7.40 | n/a |
| FY2016 | −$2.90 | −149% |
| FY2015 | $5.90 | n/a |
| FY2014 | −$1.70 | n/a |
| FY2013 | −$2.00 | −267% |
| FY2012 | $1.20 | n/a |
| FY2011 | −$3.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.05 | n/a | $0.23 | |
| Q1 FY26 | $0.22 | n/a | $0.18 | |
| Q4 FY25 | −$0.07 | −188% | −$0.09 | |
| Q3 FY25 | $0.03 | +0% | $0.06 | |
| Q2 FY25 | $0.00 | n/a | $0.06 | |
| Q1 FY25 | −$0.05 | n/a | $0.03 | |
| Q4 FY24 | $0.08 | n/a | $0.02 | |
| Q3 FY24 | $0.03 | n/a | −$0.14 | |
| Q2 FY24 | −$0.03 | −114% | −$0.21 | |
| Q1 FY24 | −$0.06 | n/a | $0.03 | |
| Q4 FY23 | −$0.08 | n/a | $0.04 | |
| Q3 FY23 | −$0.04 | n/a | $0.05 |
Against its peers
Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| VMDViemed Healthcare | $0.36 | +6% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $1.16 |
Where Protalix BioTherapeutics ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Protalix BioTherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.